Research programme: retinal cell therapy - TheraVitae

Drug Profile

Research programme: retinal cell therapy - TheraVitae

Latest Information Update: 08 Jul 2011

Price : $50

At a glance

  • Originator TheraVitae
  • Class
  • Mechanism of Action Cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • Discontinued Age-related macular degeneration; Diabetic retinopathy; Glaucoma

Most Recent Events

  • 08 Jul 2011 Discontinued - Preclinical for Glaucoma in Thailand (Injection)
  • 08 Jul 2011 Discontinued - Preclinical for Diabetic retinopathy in Thailand (Injection)
  • 08 Jul 2011 Discontinued - Preclinical for Age-related macular degeneration in Thailand (Injection)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top